The Value of Atorvastatin Over the Product Life Cycle in the United States
- 31 October 2011
- journal article
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 33 (10), 1433-1443
- https://doi.org/10.1016/j.clinthera.2011.08.014
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Heart Disease and Stroke Statistics—2011 UpdateCirculation, 2011
- Healthcare Rationing by ProxyPharmacoEconomics, 2010
- Patterns and predictors of statin prescription in patients with type 2 diabetesCardiovascular Diabetology, 2009
- JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?Cleveland Clinic Journal of Medicine, 2009
- Dynamic Cost-Effectiveness: A More Efficient Reimbursement CriterionForum for Health Economics and Policy, 2008
- An Economic Evaluation of Atorvastatin for Primary Prevention of??Cardiovascular Events in Type??2??DiabetesPharmacoEconomics, 2008
- Effects of High-Dose Atorvastatin in Patients ≥65 Years of Age With Acute Coronary Syndrome (from the Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering [MIRACL] Study)The American Journal of Cardiology, 2007
- AtorvastatinPharmacoEconomics, 2007
- Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS DrugsForum for Health Economics and Policy, 2006
- Análisis coste-efectividad del tratamiento intensivo con atorvastatina 80 mg vs. Pravastatina 40 mg en el síndrome coronario agudo: Una evaluación económica basada en el estudio PROVE-IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy)PharmacoEconomics Spanish Research Articles, 2006